Browsing by Author "Pablo Corral"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Applicability of Artificial Intelligence in the Field of Clinical Lipidology: A Narrative Review
    (2023-12-19) Walter Masson; Pablo Corral; Juan P Nogueira; Augusto Lavalle-Cobo
    Artificial intelligence (AI) has rapidly expanded its applications in medicine, including clinical lipidology. This narrative review examines the potential uses of AI, machine learning (ML), and deep learning (DL) in the diagnosis, prediction, and management of lipid disorders. Relevant studies were identified through searches of major scientific databases. Current applications include familial hypercholesterolemia detection, low-density lipoprotein cholesterol estimation, prediction of lipid goal attainment, identification of barriers to statin use, and assessment of lipid discordance. AI-based approaches show promising diagnostic and predictive performance. However, ethical concerns, transparency, reproducibility, methodological limitations, and population-specific applicability require further research and appropriate regulatory frameworks.
  • No Thumbnail Available
    Item
    Association between lipid markers in childhood/ adolescence and cardiovascular events in adulthood: A systematic review
    (2023-01-07) Walter Masson; Leandro Barbagelata; Pablo Corral; Juan P. Nogueira
    This systematic review evaluated the association between lipid markers in childhood and adolescence and cardiovascular events in adulthood. Following PRISMA guidelines, prospective observational cohort studies assessing childhood lipid levels and subsequent cardiovascular outcomes were included. Five studies involving 43,540 participants met the eligibility criteria. Elevated triglyceride levels were consistently associated with increased cardiovascular risk in adulthood. Total cholesterol and lipoprotein(a) also showed significant predictive associations, while findings for LDL-C were heterogeneous and HDL-C showed no significant association. These findings suggest that lipid abnormalities during childhood and adolescence may predict cardiovascular disease in early and middle adulthood, supporting early lipid screening and cardiovascular risk assessment.
  • No Thumbnail Available
    Item
    Dyslipidemia in adults with congenital heart disease: A systematic review and meta-analysis
    (2023-07-12) Walter Masson; Leandro Barbagelata; Martín Lobo; Pablo Corral; Juan P. Nogueira; Luciano Lucas
    This systematic review and meta-analysis evaluated dyslipidemia prevalence and lipid levels in adults with congenital heart disease. Following PRISMA guidelines, observational studies reporting dyslipidemia prevalence or comparing lipid profiles between congenital heart disease patients and controls were included. Twenty-nine studies involving 22,914 patients and 641,086 controls were analyzed. Reported dyslipidemia prevalence ranged from 14.3% to 69.9%. Quantitative analysis showed significantly lower total cholesterol, LDL-C, and HDL-C levels in patients with congenital heart disease compared with controls, while triglyceride levels showed no significant differences. Further research using standardized dyslipidemia definitions and accounting for disease complexity and confounding factors is warranted.
  • No Thumbnail Available
    Item
    Elevated Lipoprotein(a) Levels and Atrial Fibrillation: A Systematic Review
    (2023-07-17) Walter Masson; Leandro Barbagelata; Juan P Nogueira; Pablo Corral; Augusto Lavalle-Cobo; Francisco J. Romeo
    This systematic review evaluated the association between elevated lipoprotein(a) [Lp(a)] levels or related genetic variants and atrial fibrillation (AF). Following PRISMA guidelines, observational studies assessing Lp(a) concentrations or single-nucleotide polymorphisms associated with AF were systematically reviewed. Eleven studies involving 1,246,817 patients were included, comprising cross-sectional, cohort, and Mendelian randomization designs. Findings were heterogeneous: studies reported positive, inverse, or no significant associations between Lp(a) and AF. This variability prevented definitive conclusions regarding its clinical relevance. Current evidence therefore remains inconsistent, highlighting the need for further well-designed studies across diverse populations to clarify the potential relationship between Lp(a) and atrial fibrillation.
  • No Thumbnail Available
    Item
    Estratificación del riesgo cardiovascular en pacientes con obesidad – Parte I
    (2026-04-01) José Silveyra; Jorge Riera Stival; Marianella Aguirre Ackermann; María Virginia Busnelli; Ana María Cappelletti; Gustavo Alcalá; Emiliano Salmeri; Matías Arrupe; Sergio Giménez; Alicia Elbert; Guillermo De’Marziani; Melania Pajón; Juan Patricio Nogueira; Pablo Corral; Carolina Chacón; Carolina Gianoli; Ezequiel Forte; Bautista Soumoulou; Miguel Schiavone; Gustavo Lavenia; Paola Harwicz; Paula Pérez Terns
    La obesidad es una enfermedad crónica de prevalencia creciente y un importante factor de riesgo cardiovascular (RCV). Debido a la heterogeneidad de sus fenotipos clínicos y metabólicos, su evaluación debe trascender el índice de masa corporal (IMC). Este consenso intersocietario sintetiza la evidencia disponible y formula recomendaciones prácticas para evaluar y abordar el RCV en personas con obesidad. Un panel multidisciplinario revisó guías clínicas, estudios epidemiológicos, ensayos clínicos y metanálisis, aplicando el sistema GRADE. La estratificación integral debe considerar adiposidad central, puntajes de riesgo validados, comorbilidades cardiometabólicas y daño orgánico clínico y subclínico para orientar estrategias preventivas y terapéuticas personalizadas.